{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:49:30Z","timestamp":1761745770505,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>The authors present a case of a 57-year-old patient with chronic myeloid leukemia who was treated with ponatinib and subsequently treated with dasatinib. The patient showed a major molecular response; however, the BCR-ABL1 signal increased with low ponatinib and dasatinib trough concentrations. Cobicistat was used as a pharmacokinetic booster to increase ponatinib and dasatinib exposure, as opposed to increasing the dose. However, ponatinib exposure was not sufficiently increased by cobicistat. The peak dasatinib concentration was successfully increased with cobicistat treatment. Dasatinib and cobicistat cotreatment induced a response in BCR-ABL1 PCR signal, was well tolerated, and led to a substantial reduction in drug costs.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001103","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T04:03:36Z","timestamp":1685505816000},"page":"428-430","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study"],"prefix":"10.1097","volume":"45","author":[{"given":"Susan","family":"Hofman","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart F. R.","family":"Span","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thijs H.","family":"Oude Munnink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jcph.1990","article-title":"Population pharmacokinetics of ponatinib in healthy adult volunteers and patients with hematologic malignancies and model-informed dose selection for pediatric development","volume":"62","author":"Hanley","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcph.109","article-title":"Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects","volume":"53","author":"Narasimhan","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/0284186X.2017.1311024","article-title":"Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal","volume":"56","author":"Lubberman","year":"2017","journal-title":"Acta Oncol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2022.07.012","article-title":"Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: the OSIBOOST trial","volume":"171","author":"van Veelen","year":"2022","journal-title":"Lung Cancer"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"797881","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:17:14Z","timestamp":1748971034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001103","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"2023-01-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}